Sunday, August 23, 2026
21 C
Bengaluru

Indian Pharma Regional Performance Analysis & Summary

Overall Market Performance (IPM)
• The Indian Pharmaceutical Market (IPM) recorded a total value of ₹229,260.6 crore, with an overall growth of 7.6% for Dec’24.
• Out of 26 regions, 12 states/regions grew faster than the IPM growth rate of 7.6%, while the rest grew equal to or slower.

Regional Zone-Wise Performance
1. North Zone (₹62,928.3 Cr, 27% MS, 8.0% Growth)
• Top Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Delhi (₹10,756.3 Cr, 17% MS).
• Fastest Growing: Delhi (12.5%), Jammu & Kashmir (9.4%), Haryana (8.8%).
2. South Zone (₹60,758.9 Cr, 27% MS, 7.1% Growth)
• Top Contributors: Karnataka (₹13,486.8 Cr, 22% MS), Tamil Nadu (₹11,509.0 Cr, 19% MS).
• Fastest Growing: Chennai (11.6%), Telangana (8.9%), Tamil Nadu (8.2%).
3. East Zone (₹56,501.1 Cr, 25% MS, 7.4% Growth)
• Top Contributors: West Bengal (₹14,651.3 Cr, 26% MS), Bihar (₹12,078.9 Cr, 21% MS).
• Fastest Growing: Chhattisgarh (9.5%), Orissa (8.7%), Assam (7.6%).
4. West Zone (₹49,072.3 Cr, 21% MS, 8.0% Growth)
• Top Contributors: Maharashtra (₹19,780.5 Cr, 40% MS), Madhya Pradesh (₹10,154.7 Cr, 21% MS).
• Fastest Growing: Madhya Pradesh (9.8%), Maharashtra (8.6%), Gujarat (8.7%).

Key Highlights

✅ Fastest Growing State: Delhi (12.5%)
✅ Other High Growth Regions: Chennai (11.6%), Madhya Pradesh (9.8%)
✅ Largest Market Share Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Maharashtra (₹19,780.5 Cr, 40% MS), and West Bengal (₹14,651.3 Cr, 26% MS).
✅ North and West Zones had the highest growth rate (8.0%), while the South Zone had the slowest (7.1%).

Conclusion
• Delhi, Chennai, and Madhya Pradesh were the fastest-growing states.
• North and West zones led in growth, while the South zone expanded relatively slower.
• Key markets like Uttar Pradesh, Maharashtra, and West Bengal dominate market share.
• Overall, 12 states/regions outpaced the IPM growth rate of 7.6%, showing strong market potential.

Data Source: IQVIA

Hot this week

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Topics

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...
spot_img

Related Articles

spot_imgspot_img